All Type of News
Daewoong Pharmaceutical’s first shipment from new Nabota Factory
Daewoong Pharmaceutical(CEO Jong-Wook Lee) has first shipped the item which was first manufactured at ‘Nabota’ Factory 2 on the 20th. Nabota Factory 2 has acquired KGMP approval from the Ministry of Food and Drug Safe...
What are reasons Korean pharmas rarely develop novel drugs on their own?
Korean pharmaceutical companies have rarely produced self-developed novel drugs.
According to the Ministry of Food and Drug Safety(MFDS), since ‘Sunpla Inj,’ a SK Chemicals’ anticancer drug, acquired approval as the...
Huons introduce asthma treatment with new combination for first time in Korea
Huons(CEO Gi-Ahn Eum), a subsidiary of Huons Global, signed an exclusive distribution license agreement of ‘Zephirus,’ a inhaled capsule for the treatment of asthma, in Korea with Belgian Laboratoires SMB S.A.(SMB) at...
MFDS designate 85 additional national essential medicines like 5% Glucose Inj
The Ministry of Food and Drug Safety(MFDS) announced on the 20th that it would manage and control total 211 products as ‘National Essential Medicine’ by designating additional 85 medicines as ‘National Essential Medic...
2 of 3 medicines approved as orphan drug was ‘anticancer drug’ this year
This year, 2 of 3 products approved as orphan drug were reportedly an anticancer drug.
Also, 2 products were generated by Korean pharmaceutical companies as an orphan drug by acquiring the preferential sale product ...
MOHW reveals final version of ‘2nd General Plans for Pharmaceutical Industry’
The ‘2nd General Plans for the Pharmaceutical Industry’ has been finally revealed.
It kept the original plans from the last public hearing last November without major changes and revisions, containing a wide range o...
MFDS entirely separates Pharmaceutical Affairs Law into pharmacists and medicines
The current Pharmaceutical Affairs Law is expected to be divided into two separate laws for pharmacists and medicines respectively.
The Ministry of Food and Drug Safety(MFDS) reportedly secured legitimacy to legisla...
Annual interest rate of 15.5% for drug payment delays starts on 23 December
Medical institutes and medicine suppliers which delay payments for medicines for more than 6 months will need to pay annual interests of 15.5% for the payment delay.
The Ministry of Health and Welfare(Minister Neung-...
Mitsubishi Tanabe notifies Kolon Life Science cancellation of ‘Invossa’ technology agreement
Kolon Life Science(CEO Woo-Seok Lee) announced on the 19th Mitsubishi Tanabe Pharma(MTPC) notified the company cancellation of Invossa technology export and to return the upfront payment of JPY 2.5 billion(approx. KRW...
[Focus] Which will acquire CJ HealthCare for KRW 1 trillion, pharma or private equity fund?
There is now a high chance for CJ HealthCare to be purchased in some way as Kolmar Korea and Korean and foreign private equity funds have decided to join in the preliminary bidding for the company on the 18th.
Despit...
